Baird Maintains Outperform on Castle Biosciences, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $35 to $25.
June 05, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences but lowers the price target from $35 to $25.
The news of Baird maintaining an Outperform rating on Castle Biosciences indicates a positive outlook for the company. However, the lowering of the price target from $35 to $25 suggests a more conservative valuation. This mixed signal may result in a neutral short-term impact on CSTL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100